• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Zheng Y, Narwal R, Jin C, Baverel P, Gupta A, Mukhopadhyay P, Higgs B, Roskos L. Identification of prognostic and predictive factors for durvalumab efficacy by modeling of tumor response and overall survival (OS) in patients with non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
2
Zhang X, Park K, Rizvi N, Dennis P, Narwal R, Huang Y, Arani R, Mukhopadhyay P. Prediction of survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
3
Zheng Y, Jin X, Narwal R, Jin CYD, Gupta A, Ben Y, Mukhopadhyay P, Higgs B, Roskos L. Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
4
Saxena Y, Gupta R, Moinuddin A, Narwal R. Blood pressure reduction following accumulated physical activity in prehypertensive. J Family Med Prim Care 2016;5:349-356. [PMID: 27843840 PMCID: PMC5084560 DOI: 10.4103/2249-4863.192368] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
5
Rizvi N, Balmanoukian A, Goldberg S, Chaft J, Sanborn R, Rebelatto M, Narwal R, Robbins P, Gu Y, Karakunnel J, Antonia S. 418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
6
Song X, Pak M, Chavez C, Liang M, Lu H, Blake-Haskins A, Robbins P, Jin X, Gupta A, Roskos L, Narwal R. 203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30091-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
7
Antonia S, Goldberg S, Balmanoukian A, Narwal R, Robbins P, D'Angelo G, Blake-Haskins A, Karakunnel J, Rizvi N. A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
8
Lechleider R, Becerra C, Liang M, Narwal R, Shi L, Conkling P, Galsky M, Jotte R, Wu H, Vogelzang N. 404 Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72111-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA